View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
October 11, 2021

Regenxbio reports positive data from diabetic retinopathy therapy trial

RGX-314 was found to be well tolerated in Cohort 1 subjects, with no drug-related serious adverse event reported.

Regenxbio has reported preliminary results from the ongoing Phase II ALTITUDE clinical trial of RGX-314 to treat diabetic retinopathy (DR) without centre-involved diabetic macular oedema (CI-DME).

A potential one-time gene therapy, RGX-314 is currently being developed to treat wet age-related macular degeneration, as well as various other chronic retinal ailments.

The multicentre, randomised, open-label, controlled dose-escalation Phase II trial is analysing the efficacy, safety and tolerability of an in-office suprachoroidal delivery of RGX-314 given with the help of SCS Microinjector in DR patients.

Subjects included in the trial comprised people with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR).

Findings showed that RGX-314 was demonstrated to be well tolerated in the 15 subjects dosed with RGX-314 in cohort 1.

A patient receiving RGX-314 experienced a serious adverse event, which happened in the untreated fellow eye and is deemed unrelated to the treatment.

No intraocular inflammation was reported on slit-lamp examination in subjects in Cohort 1 receiving RGX-314.

One subject had mild episcleritis, which was resolved by using topical corticosteroids.

Common ocular treatment-emergent adverse events in the study eye were reported to be unrelated to the treatment and were mostly mild in nature.

A two-step or higher improvement from baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale (ETDRS-DRSS) were experienced by 33% of subjects in Cohort 1 at three months against 0% in the observational control arm.

Nearly 43% of the NPDR patients had a two-step or greater improvement following three months of RGX-314 administration.

Approximately 25% of the subjects with PDR showed a two-step or greater improvement at three months on receiving treatment, the company noted.

Regenxbio chief medical officer Steve Pakola said: “We are pleased to share initial data from the Phase II ALTITUDE trial, and we are encouraged to see treatment effect particularly at this early time point of three months after the one-time, in-office administration of RGX-314.”

“RGX-314 is the first gene therapy in clinical trials for DR using suprachoroidal delivery, and has the potential to provide sustainable, long-term anti-VEGF protein production in the eye for the treatment of DR, which affects approximately eight million people in the US alone.”

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena